FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), The First Antibody-Drug Conjugate For Treating HER2-Positive Metastatic Breast Cancer

Genentech, a member of the Roche Group recently announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla(ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news